Week in Review: MicroPort-Sorin $20 Million China JV to Begin Operations

The $20 million China medical device JV formed by MicroPort of Shanghai and Italy’s Sorin Group was granted a regulatory greenlight to begin operations; Lee's Pharm of Hong Kong in-licensed China distribution rights for Attila®, an orphan drug made by Abiogen; InSightec, an Israeli medical device maker, opened three Shanghai centers that offer its ExAblate therapy, a non-invasive treatment for uterine fibroids; WuXi PharmaTech started high-potency API operations through its Shanghai lab; participants at the recent ChinaBio Partnering Forum discussed strategies for navigating China’s drug approval regulations;  and also at the Partnering Forum, attendees presented evidence that Chinese biotechs are transforming cutting-edge discoveries into drugs, creating partnering opportunities. More details…. Stock Symbols: (HK: 00853) (MIL: SRN) (HK: 950) (NYSE: WX) Share this with colleagues: // //